Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.80), $0.17 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.13 million versus the consensus estimate of $58.88 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.